Arcoma Valuation

Is ARCOMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARCOMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ARCOMA (SEK10.4) is trading below our estimate of fair value (SEK22.79)

Significantly Below Fair Value: ARCOMA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARCOMA?

Other financial metrics that can be useful for relative valuation.

ARCOMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA8x
PEG Ratio1.3x

Price to Earnings Ratio vs Peers

How does ARCOMA's PE Ratio compare to its peers?

The above table shows the PE ratio for ARCOMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.6x
MCLR Medclair
43.9xn/aSEK 100.6m
CARE Careium
16.9x16.5%SEK 732.2m
CRAD B C-Rad
16.8x27.4%SEK 973.8m
ADDV A ADDvise Group
20.9x19.2%SEK 728.2m
ARCOMA Arcoma
10.6x7.9%SEK 137.1m

Price-To-Earnings vs Peers: ARCOMA is good value based on its Price-To-Earnings Ratio (10.6x) compared to the peer average (24.6x).


Price to Earnings Ratio vs Industry

How does ARCOMA's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a33.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a33.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: ARCOMA is good value based on its Price-To-Earnings Ratio (10.6x) compared to the European Medical Equipment industry average (29.9x).


Price to Earnings Ratio vs Fair Ratio

What is ARCOMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARCOMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.6x
Fair PE Ratio13.8x

Price-To-Earnings vs Fair Ratio: ARCOMA is good value based on its Price-To-Earnings Ratio (10.6x) compared to the estimated Fair Price-To-Earnings Ratio (13.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies